Adjustment for Generic Entry Clause Samples
The "Adjustment for Generic Entry" clause defines how contractual terms, such as pricing or royalties, are modified if a generic version of a product enters the market. Typically, this clause outlines specific triggers—such as the approval or launch of a generic competitor—and details the resulting changes, like reduced payments or altered supply obligations. Its core function is to address the financial and commercial impact of generic competition, ensuring that both parties have a clear, pre-agreed mechanism to adjust their obligations and mitigate risk when exclusivity is lost.
Adjustment for Generic Entry. If at any time FibroGen’s net margin percentage on any Product supplied to AstraZeneca falls below [ * ]) after a Generic Product is sold in any country in the Territory, FibroGen shall have the right to renegotiate the manufacturing and supply payment terms under the Supply and Quality Agreement. Upon FibroGen’s request, the Parties shall renegotiate reasonable terms in good faith, taking into account also the overall profitability of such Product to AstraZeneca.
Adjustment for Generic Entry. If at any time FibroGen’s net margin percentage on any Product supplied to AstraZeneca falls below [ * ]) after a Generic Product is
Adjustment for Generic Entry. The Transfer price payments set forth under this Agreement will be adjusted, and, in certain circumstances, FibroGen shall have the right to renegotiate or terminate this Agreement as set forth on page 21 of the EU Collaboration Agreement under the “Cost of Supply; Transfer Price Payments” section. REF: 00033249.0 14. Confidential [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
Adjustment for Generic Entry. Pursuant to Section 6.5(c) of the Collaboration Agreement, if at any time FibroGen’s net margin percentage on any Bulk Drug Product supplied to AstraZeneca falls [*] after a Generic Product (defined in the Collaboration Agreement) is sold in any country in the Territory, FibroGen shall have the right to renegotiate the manufacturing and supply payment terms under this Agreement and the Quality Assurance Agreement. Upon FibroGen’s request, the Parties shall renegotiate reasonable terms in good faith, taking into account also the overall profitability of such Finished Product to AstraZeneca.